Jefferies Boosts Target on Orexigen (OREX) as FDA Gets Close to Admitting Error
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Orexigen (OREX) Pops Higher as Contrave May Get Speedier Approval (VVUS) (ARNA)
October 22, 2012 7:51 AM EDTOrexigen Therapeutics (Nasdaq: OREX) peers VIVUS (Nasdaq: VVUS) and Arena Pharmaceuticals (Nasdaq: ARNA) are active in early trading Monday following Orexigen receiving a formal dispute resolution request (FDRR) from the FDA Center for... More
Orexigen (OREX) Said FDA Supports Faster Path to Resubmission of the Contrave NDA, Study Enrollment Surpasses 7K
October 22, 2012 7:05 AM EDTOrexigen Therapeutics, Inc. (NASDAQ: OREX) received a response to a formal dispute resolution request (FDRR) from the FDA Center for Drug Evaluation and Research (CDER).
The response indicates that CDER highly supports further discussions regarding a faster path to resubmission of the Contrave®... More
